Compare Orchid Chemicals with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs SUVEN LIFESCIENCES - Comparison Results

ORCHID PHARMA LTD     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD SUVEN LIFESCIENCES ORCHID PHARMA LTD/
SUVEN LIFESCIENCES
 
P/E (TTM) x -0.5 19.9 - View Chart
P/BV x 0.1 4.0 2.9% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 ORCHID PHARMA LTD   SUVEN LIFESCIENCES
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
SUVEN LIFESCIENCES
Mar-19
ORCHID PHARMA LTD/
SUVEN LIFESCIENCES
5-Yr Chart
Click to enlarge
High Rs194338 57.4%   
Low Rs35169 20.7%   
Sales per share (Unadj.) Rs276.552.1 530.3%  
Earnings per share (Unadj.) Rs-79.26.8 -1,159.6%  
Cash flow per share (Unadj.) Rs-43.58.6 -507.0%  
Dividends per share (Unadj.) Rs01.50 0.0%  
Dividend yield (eoy) %00.6 0.0%  
Book value per share (Unadj.) Rs53.965.3 82.6%  
Shares outstanding (eoy) m70.45127.28 55.4%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.44.9 8.5%   
Avg P/E ratio x-1.437.1 -3.9%  
P/CF ratio (eoy) x-2.629.6 -8.9%  
Price / Book Value ratio x2.13.9 54.7%  
Dividend payout %022.0 0.0%   
Avg Mkt Cap Rs m8,06732,272 25.0%   
No. of employees `0002.81.1 258.8%   
Total wages/salary Rs m2,527661 382.2%   
Avg. sales/employee Rs Th6,956.16,132.2 113.4%   
Avg. wages/employee Rs Th902.5611.1 147.7%   
Avg. net profit/employee Rs Th-1,993.0803.5 -248.0%   
INCOME DATA
Net Sales Rs m19,4776,635 293.5%  
Other income Rs m407242 168.1%   
Total revenues Rs m19,8846,877 289.1%   
Gross profit Rs m1,1031,604 68.7%  
Depreciation Rs m2,519221 1,137.9%   
Interest Rs m5,22738 13,864.2%   
Profit before tax Rs m-6,2361,587 -392.9%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-125718 -17.4%   
Profit after tax Rs m-5,580869 -641.8%  
Gross profit margin %5.724.2 23.4%  
Effective tax rate %2.045.2 4.4%   
Net profit margin %-28.713.1 -218.7%  
BALANCE SHEET DATA
Current assets Rs m11,0146,232 176.7%   
Current liabilities Rs m32,0601,490 2,151.6%   
Net working cap to sales %-108.171.5 -151.2%  
Current ratio x0.34.2 8.2%  
Inventory Days Days9586 109.8%  
Debtors Days Days3483 40.6%  
Net fixed assets Rs m29,4404,043 728.1%   
Share capital Rs m705127 553.4%   
"Free" reserves Rs m2,0438,183 25.0%   
Net worth Rs m3,8008,310 45.7%   
Long term debt Rs m9,01818 50,662.4%   
Total assets Rs m46,51010,389 447.7%  
Interest coverage x-0.243.1 -0.4%   
Debt to equity ratio x2.40 110,792.2%  
Sales to assets ratio x0.40.6 65.6%   
Return on assets %-0.88.7 -8.7%  
Return on equity %-146.910.5 -1,403.6%  
Return on capital %-3.719.5 -19.1%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,5135,622 133.6%   
Fx outflow Rs m5,6491,799 313.9%   
Net fx Rs m1,8653,822 48.8%   
CASH FLOW
From Operations Rs m1,682356 473.1%  
From Investments Rs m-9,860-279 3,539.3%  
From Financial Activity Rs m6,644-225 -2,951.5%  
Net Cashflow Rs m-1,535-148 1,035.8%  

Share Holding

Indian Promoters % 32.3 63.4 50.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 0.0 -  
FIIs % 3.3 0.0 -  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 36.5 151.5%  
Shareholders   84,811 37,287 227.5%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  DISHMAN PHARMA  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare ORCHID PHARMA LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 21 Points Higher; Banking and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day marginally higher.

Related Views on News

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFE Announces Quarterly Results (3QFY19); Net Profit Down 27.1% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUVEN LIFE has posted a net profit of Rs 252 m (down 27.1% YoY). Sales on the other hand came in at Rs 1 bn (down 21.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

More Views on News

Most Popular

7 Stocks That Will Generate Alpha over the Next Decade(Profit Hunter)

Oct 29, 2019

Here's your chance benefit from a safe approach to making money in stock markets .

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Ditch the Risky Fixed Deposits for Safer 'Bluechip Deposits'(Profit Hunter)

Oct 30, 2019

Most people think stocks are riskier than fixed deposits and bonds. The last quarter century proves otherwise.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jul 24, 2019 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 8-QTR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS